Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bexotegrast - Pliant Therapeutics

Next Previous
Drug Profile

Bexotegrast - Pliant Therapeutics

Alternative Names: PLN-74809

Latest Information Update: 03 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pliant Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Butyric acids; Naphthyridines; Quinazolines; Small molecules
  • Mechanism of Action Integrin alphavbeta1 inhibitors; Integrin alphaVbeta6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary sclerosing cholangitis
  • No development reported Primary biliary cirrhosis
  • Discontinued Idiopathic pulmonary fibrosis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 27 Jun 2025 Discontinued - Phase-II for Idiopathic pulmonary fibrosis (Treatment-experienced) in Belgium, Italy, Australia, New Zealand, Netherlands, United Kingdom, Germany, Canada, USA (PO)
  • 27 Jun 2025 Discontinued - Phase-II/III for Idiopathic pulmonary fibrosis in USA, Australia, Canada, New Zealand, Israel, South Korea, Chile, Taiwan, Argentina, Belgium, Czech Republic, Denmark, France, Netherlands, Spain, United Kingdom, Brazil, China, Germany, Greece, India, Italy, Japan, Portugal, Poland (PO)
  • 27 Jun 2025 Adverse events and efficacy data from a phase II/III BEACON-IPF trial in Idiopathic pulmonary fibrosis released by Pliant Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top